Skrifvars B, Nissilä M
Scand J Rheumatol. 1980;9(1):33-8. doi: 10.1080/03009748009098125.
In two different double-blind studies (Study 1: 27 patients with active rheumatoid arthritis in an early phase, and Study 2: 20 selected patients with rheumatoid arthritis and acute knee effusion) the efficacy of Biarison, a new non-steroidal antiinflammatory agent was compared with that of indomethacin. The daily dose of Biarison was 600-900 mg and that of indomethacin 50-100 mg. Overall clinical improvement was observed in both treatment groups, but the two treatments differ in their effects on the erythrocyte sedimentation rate (ESR) and the immunoglobulin levels in both serum and synovial fluid. In the Biarison group there was a significant decrease in ESR and serum IgG, IgM and IgA. Biarison has also been used in the treatment of active SLE (Study 3), and a good clinical improvement was noticed in 5 out of 8 patients. These preliminary results suggest that Biarison may influence the immunological processes in both rheumatoid arthritis and systemic lupus erythematosus.
在两项不同的双盲研究中（研究1：27例处于疾病早期的活动性类风湿关节炎患者；研究2：20例选定的类风湿关节炎伴急性膝关节积液患者），对一种新型非甾体抗炎药比阿瑞松（Biarison）与吲哚美辛的疗效进行了比较。比阿瑞松的日剂量为600 - 900毫克，吲哚美辛的日剂量为50 - 100毫克。两个治疗组均观察到总体临床改善，但两种治疗方法对红细胞沉降率（ESR）以及血清和滑液中的免疫球蛋白水平的影响有所不同。在比阿瑞松组中，ESR以及血清IgG、IgM和IgA显著降低。比阿瑞松也已用于治疗活动性系统性红斑狼疮（研究3），8例患者中有5例临床改善良好。这些初步结果表明，比阿瑞松可能会影响类风湿关节炎和系统性红斑狼疮中的免疫过程。
